selectION Demonstrates Safety and Disease-Modifying Mechanism of Action of its Investigational Drug, si-544, in Phase 1b Proof-of-Concept Trial in Psoriasis, a T Cell-Mediated Autoimmune Disease
- Disease modifying mechanism of action: short treatment course results in significant and durable clinical response in psoriasis patients
- si-544 is the first highly potent and selective Kv1.3 blocker to safely achieve patient plasma levels suitable for high target engagement
- Excellent safety and tolerability consistent with prior clinical experience; no dose-limiting toxicities and no serious safety signals observed
- Full immunocompetence maintained in si-544 treated patients; no immunosuppression
selectION, Inc. (“selectION” or the “Company”), a clinical-stage biopharmaceutical company developing novel treatments for T cell-mediated autoimmune diseases, today announced the successful completion of its phase 1b proof-of-concept trial evaluating si-544, a first-in-class Kv1.3 blocker in patients diagnosed with psoriasis vulgaris.
ImmunOs Therapeutics Reports Promising Clinical Activity of IOS-1002 in Advanced Solid Tumors
- Partial remissions and complete metabolic responses in PD-1/PD-L1-resistant cancers
- First-in-class multi-checkpoint inhibitor with robust efficacy and safety
- Combination arm with pembrolizumab (Keytruda®) in Australia near to completion by end 2025
ImmunOs Therapeutics AG, a clinical-stage biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and inflammatory diseases, today announced encouraging preliminary results from its ongoing Phase I clinical trial evaluating IOS-1002 in patients with advanced solid tumors.
Omnix Medical Secures $25 Million in Series C Funding Co-Led by Harel Insurance & Finance and the EIC Fund
— Existing and new investors joining forces to support the accelerated development of Omnix´s novel, first-in-class antimicrobials pipeline
— Funding underlines urgent global need for novel, resistance-proof antimicrobials
Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, announced today that it raised $25 million in a Series C funding round co-led by Harel Insurance & Finance and the EIC Fund. Existing shareholders Entree Capital, Tal Ventures, Xenia Ventures, and Oriella Limited demonstrated strong confidence in Omnix’s approach by taking part in the round alongside new external investors, including Prevail Partners and OurCrowd.
